Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesHigh-Dose Intravenous Immunoglobulin (IVIG) Therapy in Autoimmune Skin Blistering Diseases
Clinical Reviews in Allergy and Immunology, 06/30/09
Ishii N et al. - Randomized controlled trials are necessary to better determine the efficacy and adverse effects of IVIG in the treatment of autoimmune bullous skin diseases. In addition, insights into IVIG's mode of action might enable us to develop novel therapeutics to overcome the current shortage of IVIG.
Related Articles
Linear immunoglobulin A bullous dermatosis
Expert Review of Dermatology, 10/14/09
Relevance Score: 66%
Efficacy of Dapsone in the Treatment of Pemphigus and Pemphigoid: Analysis of Current Data
American Journal of Clinical Dermatology, 10/20/09
Relevance Score: 64%
Prevalence and distribution of solitary oral pigmented lesions: a prospective study
Journal of the European Academy of Dermatology and Venereology, 10/27/09
Relevance Score: 63%
Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodeficiency virus
Clinical and Experimental Dermatology, 10/08/09
Relevance Score: 63%
Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history
Expert Review of Gastroenterology & Hepatology, 10/13/09
Relevance Score: 47%
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial
BMC Infectious Diseases, 12/03/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Sponsor
Article Search
Sponsor